|
|
|||
|
||||
OverviewPeter Kruse, MD, PhD, defended his Thesis: Experimental acute pancreatitis - Models for testing a free radical mechanism at the University of Copenhagen, Denmark. Acute pancreatitis is a disease with an unclear pathogenesis and with a potential lethal outcome for the patients. One of the potential pathogenetic factors to the disease has been suggested to be free oxygen radicals as part of the inflammatory reaction. This PhD Thesis has attempted to explore the role of free oxygen radicals through two experimental models of acute pancreatitis: The Taurocholate model and the Cerulein model.Dr. Kruse has divided a nearly 30 year professional career as a physician, scientist and working for the healthcare industry for global drug, biologics and medical device companies. More about Dr. Kruse on his website: http: //www.webalice.it/morarokruse Full Product DetailsAuthor: Peter Kruse, MDPublisher: Createspace Independent Publishing Platform Imprint: Createspace Independent Publishing Platform Dimensions: Width: 21.60cm , Height: 0.40cm , Length: 27.90cm Weight: 0.213kg ISBN: 9781530340170ISBN 10: 1530340179 Pages: 82 Publication Date: 17 March 2016 Audience: General/trade , General Format: Paperback Publisher's Status: Active Availability: Available To Order We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately. Table of ContentsReviewsAuthor InformationPeter Kruse, MD, PhD, is an independent clinical consultant based in Europe with a total of 18+ years experience with the Pharmaceutical and Medical Device industry. Dr. Kruse delivers professional medical, clinical, and scientific advice and support to Pharmaceutical and Medical Device companies, Academic Institutions and Investment firms. Dr. Kruse has an special interest in building MA teams and provides education on the subject. Prior to working as an independent clinical consultant, Dr. Kruse worked in the Pharmaceutical and Device Industry: Global strategic marketing, medical affairs and global clinical development at Novo Nordisk in Europe and the US. His main responsibilities were the support and development of recombinant activated Factor VII as a hemostatic agent into surgery related indications. Dr. Kruse led a global development team that conducted clinical development in surgery. In Baxter BioSurgery, Dr. Kruse was the head of US Medical Affairs, supporting the pipeline of hemostatic devices and biologics used in surgery, devices for anti adhesion and novel treatments for wound management. He has experience in the creation and expansion of several medical affairs departments. Dr. Kruse received both his medical degree (MD) and PhD from University of Copenhagen, Denmark. He worked 12+ years as a physician at university hospitals in Copenhagen where he trained in general surgery (GI-, cardiothoracic-, urologic-, and orthopedic surgery) and intensive care. His publications are in physiology, gastroenterology and surgery. Dr. Kruse has management experience from leading medical affairs teams, global clinical development teams and several university based surgery teams. He has been an officer and a physician in the Danish Navy. Dr. Kruse has done business training through Medical Product Executive Diploma Program at Scandinavian International Management Institute and management courses including an executive course at Harvard Business School. Furthermore, Dr. Kruse has extensive drug development training from PERI, Brookwood, DIA and others. More about Dr. Kruse please visit the website: http: //www.webalice.it/morarokruse Tab Content 6Author Website:Countries AvailableAll regions |
||||